Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 181

1.

Prognostic Factors and Impact of Minimally Invasive Surgery in Early-stage Neuroendocrine Carcinoma of the Cervix.

Kim JH, Shim SH, Nam SH, Lee SW, Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT.

J Minim Invasive Gynecol. 2020 Feb 18. pii: S1553-4650(20)30094-7. doi: 10.1016/j.jmig.2020.02.004. [Epub ahead of print]

PMID:
32084588
2.

Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer.

Choi CH, Choi HJ, Lee JW, Kang ES, Cho D, Park BK, Kim YM, Kim DY, Seo H, Park M, Kim W, Choi KY, Oh T, Kang CY, Kim BG.

J Clin Med. 2020 Jan 5;9(1). pii: E147. doi: 10.3390/jcm9010147.

3.

Establishment of NOAEL for intracavernous injections of human bone marrow-derived mesenchymal stem cells in rats.

Kim JK, Jang MJ, Kim BH, Choi KR, Song G, Shin HC, Suh N, Kim YM, You D, Ahn TY, Kim CS.

Investig Clin Urol. 2020 Jan;61(1):88-98. doi: 10.4111/icu.2020.61.1.88. Epub 2019 Dec 17.

4.

Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer.

Kim HK, Lee EJ, Lee YJ, Kim J, Kim Y, Kim K, Lee SW, Chang S, Lee YJ, Lee JW, Lee W, Chun S, Son BH, Jung KH, Kim YM, Min WK, Ahn SH.

J Hum Genet. 2020 Mar;65(3):209-220. doi: 10.1038/s10038-019-0713-2. Epub 2020 Jan 6.

PMID:
31907386
5.

Endometrial thickness cut-off value by transvaginal ultrasonography for screening of endometrial pathology in premenopausal and postmenopausal women.

Park YR, Lee SW, Kim Y, Bae IY, Kim HK, Choe J, Kim YM.

Obstet Gynecol Sci. 2019 Nov;62(6):445-453. doi: 10.5468/ogs.2019.62.6.445. Epub 2019 Oct 7.

6.

Comparison of CA 125 alone and risk of ovarian malignancy algorithm (ROMA) in patients with adnexal mass: A multicenter study.

Choi HJ, Lee YY, Sohn I, Kim YM, Kim JW, Kang S, Kim BG.

Curr Probl Cancer. 2019 Nov 1:100508. doi: 10.1016/j.currproblcancer.2019.100508. [Epub ahead of print] Review.

PMID:
31708114
7.

An Improved Prediction Model for Ovarian Cancer Using Urinary Biomarkers and a Novel Validation Strategy.

Lee SW, Lee HY, Bang HJ, Song HJ, Kong SW, Kim YM.

Int J Mol Sci. 2019 Oct 5;20(19). pii: E4938. doi: 10.3390/ijms20194938.

8.

The combination of histone deacetylase and p53 expressions and histological subtype has prognostic implication in uterine leiomyosarcoma.

Baek MH, Park JY, Park Y, Kim KR, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH.

Jpn J Clin Oncol. 2019 Aug 1;49(8):719-726. doi: 10.1093/jjco/hyz059.

PMID:
31329907
10.

Histologic Correlation and Clinical Significance of Atypical Glandular Cells on Cervical Pap Tests: Analysis of 540 Cases at a Single Institution.

Jang TK, Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH.

Cancer Invest. 2019;37(1):8-15. doi: 10.1080/07357907.2018.1547738. Epub 2019 Jan 2.

PMID:
30599784
11.

Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer.

Kim JH, Yoon YS, Kim JC, Kim YM.

Anticancer Res. 2019 Jan;39(1):313-318. doi: 10.21873/anticanres.13113.

PMID:
30591474
12.

Hypoxic Preconditioned Mesenchymal Stromal Cell Therapy in a Rat Model of Renal Ischemia-reperfusion Injury: Development of Optimal Protocol to Potentiate Therapeutic Efficacy.

Jang MJ, You D, Park JY, Kim K, Aum J, Lee C, Song G, Shin HC, Suh N, Kim YM, Kim CS.

Int J Stem Cells. 2018 Nov 30;11(2):157-167. doi: 10.15283/ijsc18073.

13.

Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).

Lee JY, Park JY, Park SY, Lee JW, Kim JW, Kim YB, Jeong DH, Lee KB, Kim TH, Lee IH, Choi MC, Kim KH, Kim YM, Lee YJ, Kang S; KGOG Investigators, Pujade-Lauraine E.

Gynecol Oncol. 2019 Jan;152(1):61-67. doi: 10.1016/j.ygyno.2018.10.031. Epub 2018 Nov 6.

PMID:
30409490
14.

Comparison of Laparoscopic and Open Surgery for Patients With Borderline Ovarian Tumors.

Jung HJ, Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH.

Int J Gynecol Cancer. 2018 Nov;28(9):1657-1663. doi: 10.1097/IGC.0000000000001358.

PMID:
30335651
15.

Trends in treatment during the last stages of life in end-stage gynecologic cancer patients who received active palliative chemotherapy: a comparative analysis of 10-year data in a single institution.

Jang TK, Kim DY, Lee SW, Park JY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH.

BMC Palliat Care. 2018 Aug 7;17(1):99. doi: 10.1186/s12904-018-0348-7.

16.

Erratum: Correction of Acknowledgements.

Park YR, Kim YM, Lee SW, Lee HY, Lee GE, Lee JE, Kim YT.

Obstet Gynecol Sci. 2018 Jul;61(4):537. doi: 10.5468/ogs.2018.61.4.537. Epub 2018 Jul 10.

17.

Optimization to detect TP53 mutations in circulating cell-free tumor DNA from patients with serous epithelial ovarian cancer.

Park YR, Kim YM, Lee SW, Lee HY, Lee GE, Lee JE, Kim YT.

Obstet Gynecol Sci. 2018 May;61(3):328-336. doi: 10.5468/ogs.2018.61.3.328. Epub 2018 May 8. Erratum in: Obstet Gynecol Sci. 2018 Jul;61(4):537.

18.

The role of preoperative serum cancer antigen 125 in malignant ovarian germ cell tumors.

Kim JH, Park JY, Kim JH, Kim YM, Kim YT, Nam JH.

Taiwan J Obstet Gynecol. 2018 Apr;57(2):236-240. doi: 10.1016/j.tjog.2018.02.012.

19.

Current medical treatment of uterine fibroids.

Sohn GS, Cho S, Kim YM, Cho CH, Kim MR, Lee SR; Working Group of Society of Uterine Leiomyoma.

Obstet Gynecol Sci. 2018 Mar;61(2):192-201. doi: 10.5468/ogs.2018.61.2.192. Epub 2018 Feb 13. Review.

20.

Androgen receptor as a prognostic biomarker and therapeutic target in uterine leiomyosarcoma.

Baek MH, Park JY, Park Y, Kim KR, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH.

J Gynecol Oncol. 2018 May;29(3):e30. doi: 10.3802/jgo.2018.29.e30. Epub 2018 Feb 5.

Supplemental Content

Loading ...
Support Center